After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Moderna (MRNA-1.32%), a leader in the field of messenger RNA (mRNA)-based vaccines and therapeutics, is a prime example. The company's stock price skyrocketed in 2021, thanks to the strong sales ...

Moderna (NASDAQ: MRNA) was the top-performing stock in the S&P 500 not too long ago when the company joined the index in mid-2021. At its peak in 2021, the company's value soared to $187 billion ...

Overall, the performance of MRNA stock with respect to the index has been quite volatile. Returns for the stock were 143% in 2021, -29% in 2022, and -45% in 2023.

The bigger story for Moderna, however, is that it should soon expand beyond COVID-19. The U.S. Food and Drug Administration (FDA) has set a PDUFA date of May 12, 2024, for its approval decision on ...

Moderna stock declined by about 30% over the last week (five trading days) following the company’s weaker than expected Q3 2021 results. While Moderna’s revenue for Q3 grew by almost 13% ...